Understanding how resistance arises in lung cancer is key to figuring out how to eliminate a tumor.
Preventing lung cancer's unwelcome return - Cold Spring Harbor Laboratory
Source : https://www.cshl.edu/preventing-lung-cancers-unwelcome-return/
When a doctor gives a patient antibiotics for a bacterial infection, they usually require them to finish the entire treatment, even when symptoms go away. This is to ensure the...
Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34221980/
doi: 10.3389/fonc.2021.665484. 1 Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. 2 Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China....
“The declines in lung cancer and melanoma death rates are the result of progress across the entire cancer continuum — from reduced smoking rates to prevent cancer to discoveries such as targeted drug therapies and immune checkpoint inhibitors,” said Karen E. Knudsen, ., Ph.D., chief executive officer, American Cancer Society....
Drugging the Undruggable: Advances on RAS Targeting in Cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34200676/
Around 20% of all malignancies harbour activating mutations in RAS isoforms. Despite this, there is a deficiency of RAS-targeting agents licensed for therapeutic use. The picomolar affinity of RAS for...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In the current study, researchers assessed the preclinical and clinical evidence underlying the efficacy of KRAS-G12C inhibitor monotherapy, as well as examining combination therapies created to overcome primary Show More
Aspirin-Triggered Resolvin D1 Reduces Proliferation and the Neutrophil to Lymphocyte Ratio in a Mutant KRAS-Driven Lung Adenocarcinoma Model - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34203378/
Tumour-associated neutrophils (TANs) can support tumour growth by suppressing cytotoxic lymphocytes. AT-RvD1 is an eicosanoid that can antagonise neutrophil trafficking instigated by ALX/FPR2 ligands such as serum amyloid A (SAA)....